Skip to main content
Global HIV Vaccine Enterprise

Global HIV Vaccine Enterprise

What the Global HIV Vaccine Enterprise does

The Global HIV Vaccine Enterprise promotes HIV vaccine development by sharing knowledge, fostering collaboration, prioritizing HIV vaccine R&D on the global health agenda, and supporting early-career African researchers and advocates through capacity-building initiatives. It was established in 2003 and became a programme of the IAS in 2018.

The Global HIV Vaccine Enterprise in context

Although there are multiple HIV prevention options, access and uptake are uneven, which means that HIV incidence remains worryingly high in some areas and populations. An HIV vaccine holds the key to halting the pandemic by decreasing transmission and new acquisitions of HIV.

I’m very excited now that I’m in the room with such great minds, especially for someone from Lesotho. After the HIV Vaccine Advocacy Academy, now they will hear from me!

2023 HIV Vaccine Advocacy Academy participant

The Global HIV Vaccine Enterprise in action

The Global HIV Vaccine Enterprise shares knowledge, fosters collaboration, enables solutions and expands support critical to the development of – and future access to – an HIV vaccine.

The IAS Global HIV Vaccine Enterprise:

  • Strengthens the HIV vaccine pipeline by encouraging diverse approaches in HIV vaccine research and advancing the HIV vaccine portfolio

  • Expands and diversifies engagement and resources by fostering interest in HIV vaccine R&D and broadening research talent within the HIV vaccine field

  • Mobilizes knowledge to accelerate product development by driving opportunities to address unanswered scientific questions and leveraging synergies with other infectious disease research

Key numbers

Upcoming activities

In partnership with

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.